Home Artificial Intelligence Nemaura Medical to Present at Virtual Diabetes Technology Meeting 2020

Nemaura Medical to Present at Virtual Diabetes Technology Meeting 2020

0
43

LOUGHBOROUGH, England, Oct. 22, 2020 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it will present on Day 1 of the Virtual Diabetes Technology Meeting 2020 on November 12, 2020 at 2:50 PT. Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will give a presentation titled “CGM Usage for the Management and Reversal of Type 2 diabetes.”

Due to the impact of COVID-19, the 20th Annual Diabetes Technology Meeting will be held as a virtual event. The meeting’s goal is to connect technology developers and users to facilitate the creation of new and cost-effective tools to help people with diabetes. FDA officials also participate in the meeting and will update attendees on current U.S. regulatory policies. The sharing of original data is particularly emphasized, too.   The format of the meeting will include state-of-the-art lectures, oral presentations of abstracts, panel discussions with Q & A sessions, and virtual poster sessions. Investors wishing to view Dr. Chowdhury’s presentation can register for the meeting at https://www.diabetestechnology.org/dtm/.

In December 2020 in the U.S., Nemaura plans to launch proBEAT™, a non-invasive, wearable, glucose monitor which is expected to help users improve their knowledge of how a range of lifestyle, dietary and health and wellbeing factors impact their sugar levels by acting like a black box flight recorder. Big data about the multitude of factors that affect glucose levels will be gathered and used to provide artificial intelligence based feedback and prompts.  This will be combined with a behavioral change and weight management digital app in-licensed from Healthimation Inc. and is expected to collectively help diabetic and pre-diabetic patients better manage, reverse, or prevent the onset of diabetes.   In the U.S., there are currently 88 million patients considered to be pre-diabetic and 25 million patients with Type 2 diabetes. Worldwide, there are 420 million patients with diabetes and over 1 billion people considered pre-diabetic.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and is expected to be launched in the U.S. as a general wellness product.  

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Cautionary Statement Regarding Forward-Looking Statements:

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here